Search the Newsreel

Collegium Pharmaceutical (COLL) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 8:00 a.m. ET CALL PARTICIPANTS Head of Investor Relations - Ian Karp President and Chief Executive Officer - Vikram Karnani Chief Financial Officer - Colleen Tupper Full Conference Call Transcript Operator: Greetings, and …

Pyxis Oncology, Inc. Q2 2026: Revenue $0 EPS $(0.40) — 10-Q Summary

Pyxis Oncology, Inc. reported its Q2 2026 financial results, showing $0 in revenue and a net loss of $25.35M, leading to a diluted EPS of $(0.40). This compares to Q2 2025 revenue of $2.82M and a net loss of $18.35M. The company highlighted continued …

Form 8K Pyxis Oncology Inc For: 13 August By Investing.com

This article announces that Pyxis Oncology Inc. has filed a Form 8K on August 13. The brief piece provides no further details beyond the filing announcement. It includes stock market data and other Investing.com features.

Americold (COLD) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 8 a.m. ET CALL PARTICIPANTS Vice President, Investor Relations - Rich LelandChief Executive Officer - Rob ChambersChief Financial Officer - Chris Papa TAKEAWAYS Adjusted FFO per Share -- $0.35 for the second quarter, …

UBS verlaagt Coca-Cola Europacific Partners ondanks hogere Q2-omzet en volumes

Wedbush Adjusts Price Target on Kura Oncology to $38 From $36, Keeps Outperform Rating

Wedbush has increased its price target for Kura Oncology (KURA) shares to $38 from $36, while maintaining an Outperform rating on the stock. This adjustment comes as the company continues its clinical development in precision medicine for cancer treatment. Kura Oncology is focused on …

Collegium gains on accelerated share buybacks (COLL:NASDAQ)

Collegium Pharmaceutical (COLL) saw its stock rise in premarket trading after announcing an accelerated share repurchase agreement with Jefferies (JEF) to buy back $50 million of its company stock. This accelerated buyback is part of a larger $150 million share repurchase program authorized by …

UBS Group Upgrades Lincoln Electric (NASDAQ:LECO) to Strong-Buy

UBS Group has upgraded Lincoln Electric (NASDAQ:LECO) to a "strong-buy" rating, joining other analysts with a generally positive outlook. The company recently reported strong quarterly earnings, beating analyst estimates with EPS of $2.93 and revenue of $1.22 billion. Institutional investors hold a significant stake …

Lincoln National Corporation (LNC) Stock Forecasts

An Argus report from August 12, 2026, has lowered the target price for Lincoln National Corporation (LNC) stock to $47.00. The company, which operates various insurance and retirement businesses, is currently trading at $45.28. The report provides an overview of LNC's operating segments, including …

Collegium Pharmaceutical launches $50M accelerated share repurchase under $150M buyback program

Collegium Pharmaceutical has initiated a $50 million accelerated share repurchase (ASR) program with Jefferies, receiving an initial 1,556,420 shares. This ASR is part of a larger $150 million board-authorized buyback program, with the final share count to be determined by the volume-weighted average price …

Collegium Announces $50 Million Accelerated Share Repurchase Program

Collegium Pharmaceutical, Inc. announced an Accelerated Share Repurchase (ASR) agreement with Jefferies LLC to repurchase $50 million of its common stock. This ASR is part of a larger $150 million share repurchase program, leaving $100 million remaining after this transaction. The company believes its …

Pyxis Oncology expects two MICVO cancer-study data updates in 2026

Pyxis Oncology reported a Q2 2026 net loss of $25.3 million but strengthened its financial position with a private placement of up to $114 million, extending its cash runway into Q2 2027. The company anticipates key clinical data readouts for its lead candidate, MICVO, …

Pyxis Oncology Reports Second Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones

Pyxis Oncology (Nasdaq: PYXS) reported its second-quarter 2026 financial results, highlighting progress in its MICVO clinical development programs and an extended cash runway into Q2 2027 following a $114 million private placement. The company is set to release updated data from the MICVO Phase …

Why is Cullinan Oncology stock surging today? By Investing.com

Coca-Cola wird für mehr als Defensive bezahlt

Lincoln Educational Services Corporation Just Reported A Surprise Profit And Analysts Updated Their Estimates

Is Lincoln Electric Holdings (LECO) Undervalued On Strong Earnings And Buybacks?

Lincoln Electric Holdings (LECO) has garnered attention due to strong Q2 and H1 2026 results and ongoing share buybacks, leading to significant share price returns. While the most popular valuation narrative suggests the stock is 2% undervalued with a fair value of $294.11, its …

Wasatch Advisors LP Lowers Stock Position in Lincoln Educational Services Corporation $LINC

Wasatch Advisors LP significantly reduced its stake in Lincoln Educational Services Corporation (LINC) by 29.5% during the second quarter, selling 229,376 shares but still retaining a substantial holding worth $27.3 million. Despite this reduction and some negative analyst revisions, Lincoln Educational Services reported strong …

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Americold Realty Trust, Inc. - COLD

Pomerantz LLP is investigating Americold Realty Trust, Inc. (NYSE: COLD) for potential securities fraud. This investigation follows Americold's disclosure of a $305 million to $320 million non-cash impairment charge due to terminating and winding down operations at two automated distribution centers, which caused a …

UBS verlaagt rating Coca-Cola Europacific Partners wegens waardering

Lincoln Pharmaceuticals consolidated net profit rises 30.89% in the June 2026 quarter

Columbia Sportswear Navigates Softer Canadian Wholesale Sales

Columbia Sportswear experienced a high-single-digit decline in Canadian sales during Q2 2026, mainly due to lower wholesale orders and shipment timing, despite growth in direct-to-consumer sales. Canada remains a crucial market, accounting for nearly seven percent of global revenue, with wholesale being a significant …

UBS downgrades Coca-Cola Europacific Partners stock rating on valuation

UBS downgrades Coca-Cola Europacific Partners stock rating on valuation By Investing.com

Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri

Citius Oncology, a biopharmaceutical company, announced the appointment of Jonathan Peri, Ph.D., J.D., as an independent director to its Board, expanding it to nine members. Dr. Peri brings extensive leadership experience in higher education, financial services, law, and corporate governance, which is expected to …

Die Coca-Cola-Aktie nähert sich dem Jahreshoch und überzeugt mit solider Guidance

Lincoln Pharma Q1 Results: Net profit rises 31% YoY to ₹36.2 crore

Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. Report Zipalertinib Plus Chemotherapy Meets Primary Endpoint in Phase 3 Rezilient3 Trial in First-Line Egfr Exon 20 Insertion Mutation Non-Small Cell Lung Cancer

Taiho Oncology, Taiho Pharmaceutical, and Cullinan Therapeutics announced that their Phase 3 REZILIENT3 trial met its primary endpoint, showing a statistically significant and clinically meaningful improvement in progression-free survival for zipalertinib combined with chemotherapy in first-line EGFR exon 20 insertion mutation non-small cell lung …

Cullinan, Taiho's Zipalertinib - Chemotherapy Combo Meets Key Goal In Phase 3 NSCLC Trial; Stock Up

(RTTNews) - Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. (CGEM) announced that the Phase 3 REZILIENT3 trial, evaluating the combination of zipalertinib and platinum-based chemotherapy in the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC), met …

Coca-Cola Consolidated (COKE) After Mixed Earnings Is The Valuation Case Still Compelling

Nicolet Bankshares Inc. (NIC) Stock Forecasts

Argus has issued an investment rating of BUY for Nicolet Bankshares Inc. (NIC), setting a target price of $195.00. The current price for NIC is $177.41. The report highlights high subratings for industry, management, financial strength, growth, and value, with a medium safety subrating.

Columbia Financial (CLBK) director Sorrentini discloses direct and indirect shareholdings

Columbia Financial (CLBK) director Lucy Sorrentini has reported her initial ownership of the company's Common Stock in a Form 3 filing. As of July 20, 2026, she directly holds 32,716 shares and indirectly holds an additional 16,896 shares through a stock-based deferral plan and …

Columbia Financial (CLBK) director details options and share holdings in Form 3

Columbia Financial, Inc./MD/ director Michael Massood Jr. filed an initial ownership report (Form 3) detailing his equity positions in the company. The report indicates direct ownership of 94,613 shares of common stock and 183,246 stock options with an exercise price of $7.10, exercisable until …

Columbia Financial (CLBK) director lists stock and option holdings

Elizabeth E. Randall, a director at Columbia Financial, Inc. (CLBK), has reported her initial beneficial ownership of company securities. Her holdings include stock options for 137,442 shares with an exercise price of $7.10 and various direct and indirect common stock holdings totaling over 230,000 …

Aboitiz Equity Ventures Inc (ABOIF) (Q2 2026) Earnings Call Highlights: Net Income Surges 65% ...

This article first appeared on GuruFocus. Consolidated Net Income After Tax (NIAT): PHP13.6 billion, up 65% year-on-year. Beneficial EBITDA: PHP37.9 billion for the first half, a 25% increase year-on-year. Aboitiz Power Contribution: PHP10 billion, up 44% year-on-year. Union Bank Contribution: PHP3.4 billion, more than …

SLC (SLCE3) | Revisão de resultados do 2T26: Fundamentos Construtivos